Contineum Therapeutics (NASDAQ:CTNM) Price Target Raised to $20.00 at Robert W. Baird

Contineum Therapeutics (NASDAQ:CTNM) had its price target hoisted by Robert W. Baird from $14.00 to $20.00 in a report released on Friday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other equities analysts have also recently issued reports on the stock. Wall Street Zen upgraded shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Royal Bank Of Canada lowered their price target on shares of Contineum Therapeutics from $25.00 to $22.00 and set an “outperform” rating for the company in a report on Friday, November 21st. Morgan Stanley reissued an “equal weight” rating and set a $14.00 price objective (down from $23.00) on shares of Contineum Therapeutics in a report on Thursday, January 8th. Leerink Partners began coverage on Contineum Therapeutics in a report on Thursday, November 13th. They issued an “outperform” rating and a $22.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Contineum Therapeutics in a research report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Contineum Therapeutics has an average rating of “Moderate Buy” and an average price target of $20.20.

Contineum Therapeutics Stock Up 0.5%

CTNM stock traded up $0.07 during midday trading on Friday, reaching $13.88. 191,884 shares of the company’s stock traded hands, compared to its average volume of 201,835. The company has a 50-day simple moving average of $13.36 and a two-hundred day simple moving average of $12.03. Contineum Therapeutics has a 1-year low of $3.35 and a 1-year high of $16.33. The company has a market cap of $405.02 million, a price-to-earnings ratio of -6.37 and a beta of 1.07.

Contineum Therapeutics (NASDAQ:CTNM) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.01. Equities research analysts forecast that Contineum Therapeutics will post -2.01 EPS for the current year.

Institutional Investors Weigh In On Contineum Therapeutics

Several large investors have recently modified their holdings of CTNM. Strs Ohio bought a new position in Contineum Therapeutics during the first quarter valued at $27,000. China Universal Asset Management Co. Ltd. bought a new stake in Contineum Therapeutics during the 4th quarter valued at $43,000. Qube Research & Technologies Ltd purchased a new stake in shares of Contineum Therapeutics during the second quarter worth $43,000. Marex Group plc bought a new position in shares of Contineum Therapeutics in the second quarter worth $45,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Contineum Therapeutics in the second quarter valued at $76,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.